Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy.

Zhou, Xinna

Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy. [electronic resource] - International journal of clinical pharmacology and therapeutics Nov 2015 - 914-22 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

0946-1965

10.5414/CP202391 doi


Aged
Antineoplastic Agents, Alkylating--adverse effects
Biotransformation
Breast Neoplasms--drug therapy
Chi-Square Distribution
China
Cytochrome P-450 CYP2B6--genetics
Cytochrome P-450 CYP3A--genetics
Disease Progression
Disease-Free Survival
Female
Genotype
Glutathione S-Transferase pi--genetics
Humans
Logistic Models
Middle Aged
Multivariate Analysis
Neoplasm Metastasis
Odds Ratio
Patient Selection
Pharmacogenetics
Phenotype
Polymorphism, Single Nucleotide
Retrospective Studies
Risk Factors
Salvage Therapy
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Thiotepa--adverse effects
Time Factors
Treatment Outcome
Triethylenephosphoramide--adverse effects